Document is current
Any future updates will be listed below
-
Authors
Bashor, Caleb J. https://orcid.org/0000-0003-1354-2098
Hilton, Isaac B. https://orcid.org/0000-0002-3064-8532
Bandukwala, Hozefa
Smith, Devyn M.
Veiseh, Omid https://orcid.org/0000-0003-1153-8079
- License Information
-
More Information
Article History
Accepted: 21 April 2022
First Online: 30 May 2022
Competing interests
: All authors are inventors on several patents in the field of cell-based therapeutics, biomaterials, genome editing and genetic engineering that are owned by their current or former employers. D.M.S. holds equity in Sigilon Therapeutics and is currently an employee and shareholder of Arbor Bio. H.B. holds equity in Sigilon Therapeutics and is currently an employee and shareholder of Flagship Pioneering. O.V. is co-founder, holds equity in and receives consulting payments from Sigilon Therapeutics, Pana Bio, Avenge Bio and Curada Bio. O.V. has received compensation for consulting from Establishment Labs and Auregen Bio Therapeutics SA. The views presented here should not be considered as endorsements of any specific product or company.
